Annovis Bio Announces Phase III Study Results For Buntanetap In Parkinson's Disease; Demonstrates Dose-Dependent And Statistically Significant Cognitive Improvements; Shows Significant Improvement In MDS-UPDRS Scores For Patients With Over 3-Year Diagnosis And Those With Postural Instability And Gait Difficulties; Achieves Statistically Significant Improvements In All Primary And Secondary Endpoints
Portfolio Pulse from Benzinga Newsdesk
Annovis Bio announced positive Phase III study results for Buntanetap in treating Parkinson's Disease. The study demonstrated dose-dependent and statistically significant cognitive improvements, significant improvement in MDS-UPDRS scores for patients with over 3-year diagnosis and those with postural instability and gait difficulties, and achieved statistically significant improvements in all primary and secondary endpoints.
July 02, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Annovis Bio's Phase III study results for Buntanetap in Parkinson's Disease show significant cognitive and motor improvements, achieving statistically significant results in all primary and secondary endpoints.
The positive Phase III study results for Buntanetap in treating Parkinson's Disease are likely to boost investor confidence in Annovis Bio. The statistically significant improvements in cognitive and motor functions, along with achieving all primary and secondary endpoints, suggest strong efficacy of the drug, which could lead to increased market interest and potential future revenue growth.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100